抗病毒药物的药物经济学研究文献质量评价：中药与非中药的比较
Quality Appraisal of the Pharmacoeconomic Research Literature about Antivirals: A Comparison between Chinese Medicine and Non-Chinese Medicine.
作者信息
Zhang Junliang, Bai Qian, Bian Ying
机构信息
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao, China.
出版信息
Evid Based Complement Alternat Med. 2021 Jul 14;2021:5537435. doi: 10.1155/2021/5537435. eCollection 2021.
INTRODUCTION
Antiviral activity is a main function of many types of traditional Chinese medicine (TCM), and they may contribute more in the process of certain viral epidemics. Therefore, based on the effectiveness and economy of TCM, we aimed to determine the situation of health economic studies about antivirals, especially the difference between TCM and non-TCM.
METHODS
A literature search of three databases was conducted with a time range of January 2000-December 2020, and terms related to health economics and TCM were used as key terms. QHES and CHEERS were used as quality assessment tools.
RESULTS
203 papers were included in our research. After evaluation using QHES and CHEERS, antiviral TCM obtained an overall score of 41.37 ± 4.46/99 in QHES, compared with 48.89 ± 7.25/99 (18.18% higher than TCM) of antiviral non-TCM.
CONCLUSION
With a statistically significant difference, the overall quality of pharmacoeconomic research about antiviral non-Chinese medicine is better than that about antiviral Chinese medicine, which may have resulted from researchers' capacities or the absence of a more suitable standard for pharmacoeconomic research. It tells that the quality of pharmacoeconomic studies about TCM still warrants improvement.
引言
抗病毒活性是多种传统中药的主要功能，在某些病毒流行过程中它们可能发挥更大作用。因此，基于中药的有效性和经济性，我们旨在确定抗病毒药物卫生经济学研究的情况，尤其是中药与非中药之间的差异。
方法
对三个数据库进行文献检索，时间范围为2000年1月至2020年12月，使用与卫生经济学和中药相关的术语作为关键词。采用QHES和CHEERS作为质量评估工具。
结果
我们的研究纳入了203篇论文。使用QHES和CHEERS进行评估后，抗病毒中药在QHES中的总体得分为41.37±4.46/99，相比之下，抗病毒非中药的得分为48.89±7.25/99（比中药高18.18%）。
结论
抗病毒非中药的药物经济学研究总体质量在统计学上显著高于抗病毒中药，这可能是由于研究人员的能力问题或缺乏更合适的药物经济学研究标准所致。这表明中药药物经济学研究的质量仍有待提高。
Zotero 插件